After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease. | BioVie is eyeing a ...

Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy. | Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its ...

Generate Biomedicines IPO highlights AI-driven drug discovery, strong backing, promising pipeline, and investor confidence signals.

After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.

More than 10 pre-profit drug developers are seeking Hong Kong listings as AI-powered biotech platforms draw growing investor interest More than 10 loss-making biotechnology companies have filed for ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

The biotech industry’s challenging years might finally be giving way to more optimism as a new funding wave takes shape.

The life sciences industry is poised for an upswing in initial public offering (IPO) activity in 2026, supported by a large IPO backlog, the strong performance of biotech market indices, and positive ...

Jan 7 (Reuters) – Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand ...